ABSTRACT (Currently 300/300) Background. Dextromethorphan 20mg /quinidine 10mg (DM/Q) was approved to treat
INTRODUCTION
Traumatic brain injury (TBI) is associated with a broad range of emotional and behavioral disturbances that are often distressing for affected individuals, their family members and caregivers. [1] Pseudobulbar affect (PBA) is among the disorders of emotion regulation affecting people with TBI and is characterized by sudden, uncontrollable outbursts of laughing and/or crying that are independent of mood and out of proportion or incongruous to social context. [2, 3, 4] PBA episodes tend to be stereotypical and can last for seconds to several minutes, occur multiple times per day, and cause clinically significant distress. [2] PBA episodes can result in embarrassment, social isolation, and occupational disability. [3] The pathophysiology of PBA is incompletely understood, but brain lesions of various etiologies (inflammatory, ischemic, hemorrhagic, or neurodegenerative) involving the corticobulbar tracts, extrapyramidal region, or subcortical areas, particularly subcortical white matter, have been associated with the uncontrollable laughing or crying episodes of PBA. [5, 6] The diagnosis of PBA is based on patient history and neurological examination, but PBA is generally under-recognized due to lack of routine screening, limited awareness of the condition, and confusion with other neuropsychiatric conditions. [4, 7, 8] In the absence of specific questioning, patients may fail to describe PBA episodes to their physicians or may describe them non-specifically, leading to lack of identification or misattribution to mood or other disorders. These factors may play a role in the wide range of estimated prevalence rates for PBA in people with TBI. Based on patient interviews, PBA has an estimated prevalence of 5 to 30% within the first year following TBI, [9, 10, 11] but other PRISM II TBI Cohort 3 studies have reported some degree of uncontrollable crying or laughing in up to 48% and even 66% with mild TBI as measured using the self-reported Center for Neurologic Study-Lability Scale (CNS-LS). [7, 12, 13] The CNS-LS is a tool to measure laughing and crying episode frequency and severity; it was developed and validated using patient samples with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). [14, 15] A CNS-LS score of ≥13 in these studies was found to predict a neurologist diagnosis of PBA for 82% of study participants with ALS and 78% with MS, and CNS-LS scores correlated well with PBA episode frequency.
Currently, the only drug approved by the US Food and Drug Administration for the treatment of PBA is the fixed combination of dextromethorphan (DM) and quinidine (Q) (Nuedexta ® [DM/Q]; Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA). [16, 17] Limited evidence also suggests efficacy for some antidepressants; however these are not FDA-approved for PBA. [3, 18, 19, 20, 21, 22, 23] In the United States, the approved DM/Q dose for PBA is 20mg/10 mg twice daily. [16] DM is a weak, uncompetitive N-methyl-D-aspartate receptor antagonist, a moderate affinity sigma-1 receptor agonist, a serotonin and norepinephrine reuptake inhibitor, and days of waking hours with the patient for the week prior to clinic visits (to be knowledgeable about PBA episodes).
Outcome Measures
The primary endpoint was change in CNS-LS score from baseline to day 90 (or final visit if early withdrawal). The CNS-LS is a 7-item measure of affective lability of laughing and crying [14, 15] with scores ranging from 7 to 35 (higher scores indicating higher frequency and/or severity of PBA episodes).
PRISM II TBI Cohort The QOL-VAS is an anchored, continuous line scale that assesses the impact of PBA episodes on the participant's global subjective well-being (0 = not at all affected to 10 = significantly affected) during the past week. CGI-C and PGI-C [35] are completed by the investigator and the participant (or caregiver), respectively, and assess overall change in condition and treatment response on a Likert-type scale (1 = very much improved to 7 = very much worse). The NFI is a standardized self-reported rating scale for TBI, composed of 76 items organized into 6 independent scales (depression, somatic, memory/attention, communication, aggression, and motor). [36] The MMSE [37] comprises 11 questions or simple tasks assessing orientation, memory, attention, and language to evaluate the patient's cognitive state (scored from 0 to 30). The PHQ-9 is a 9-item scale that assesses depressive symptoms, scored from 0 to 27 (with higher scores indicating greater severity). The treatment satisfaction question is completed by the patient (or caregiver) and rates satisfaction with DM/Q treatment as very dissatisfied, somewhat dissatisfied, neither satisfied nor dissatisfied, somewhat satisfied, and very satisfied. All scales were completed at day 90; the CNS-LS, PBA episode count and PRISM II TBI Cohort 8 PHQ-9 were also completed at day 30. AEs occurring any time from enrollment to 30 days after the last dose of DM/Q were recorded.
Statistical Analysis
The safety population included all study participants who received at least one dose of DM/Q. For the effectiveness analysis, a modified intent-to-treat (mITT) population was utilized in which study participants were included if they met all study eligibility criteria, received at least one dose of DM/Q, had at least one post-baseline CNS-LS score, and were without significant site non-compliance. Unless otherwise specified, statistical tests were two-tailed and carried out at the α = 0.05 level of significance; all analyses were completed using either SAS v9. The primary analysis tested the null hypothesis that the mean change in CNS-LS score from baseline to the day 90 visit was equal to zero; the 95% confidence interval (CI) also was calculated to enable a pre-specified descriptive comparison with the CNS-LS change observed in the 12-week, phase 3, pivotal registration trial (the STAR trial) conducted in study participants with PBA secondary to ALS or MS that led to the US approval of DM/Q for PBA.
[31]
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Changes from baseline were analyzed inferentially using one-sample t-tests for rating scale measures (CNS-LS, QOL, NFI, MMSE, and PHQ-9). To estimate change in PBA episode counts, a mixed-effects Poisson regression model was used, with number of PBA episodes in the past seven days as the dependent variable and age, gender, and time (day 30 and day 90) as fixed effects, while allowing for individual differences in baseline rate (a random subject effect). The percentage change in episode rate from baseline to a given visit is 1 minus the appropriate time parameter (λ). Associations between variables were estimated using the Pearson correlation coefficient and the null hypothesis that the true correlation was equal to zero was assessed using two-sided tests. AEs were categorized via Medical Dictionary for Regulatory Activities (MedDRA version 15.1) coding and reported descriptively.
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RESULTS
Participants
Patient disposition is summarized in Figure 1 . Of the 130 study participants screened, 120 were enrolled and received at least one dose of DM/Q (safety population). A total of 74 (61.7%) study participants completed the study through day 90. Early discontinuations were most commonly due to AEs (11.7%) and loss to follow up (8.3%). A total of 33 study participants were excluded from the effectiveness analysis set due to any or all:
lack of post-baseline CNS-LS score (n = 19), failure to meet all inclusion criteria (n = 9), or site non-compliance (n = 9). The day 30 mITT analysis population included 87 study participants, and 67 study participants with available assessments at day 90.
Baseline demographics and clinical characteristics of the safety population are described in Table 1 . Mean (SD) patient age was 45.7 (14.1) years, and 95.8% lived at home. Based on protocol criteria described above, 48 (40%) study participants were classified as having mild TBI, 48 (40%) moderate, and 24 (20%) severe. The most common injury mechanism was due to motor vehicle accident (55.8%). A large proportion of study participants were taking one or more concomitant psychiatric medications at baseline (70.0%), most commonly antidepressants (42.5%), followed by anxiolytics or sedatives (38.3%). The mean (SD) CNS-LS score for the mITT population at baseline was 20.5 and median of 10 (range: 0, 80; Table 1 ).
Primary Effectiveness Endpoint
The mean (SD) changes from baseline in CNS-LS score at day 30 and day 90/final visit were -5.6 (5.2) and -8.5 (5.2) respectively, which represent significant improvements compared to baseline (P<.001, both; Figure 2 ). The mean (95% CI) improvement of -8.5
( A majority of study participants indicated they were very satisfied or somewhat satisfied with DM/Q treatment; less than 10% were dissatisfied. (Figure 5b ). Correlation analysis demonstrated that CNS-LS score reduction from baseline to day 90 was significantly correlated with improvements on QOL-VAS, PGIC, CGIC, and the PHQ-9, but not with patient satisfaction, weekly PBA episode count, and MMSE scores ( Table 2) . Despite the lack of association of change scores between CNS-LS and PBA episode count, absolute CNS-LS score did show significant correlation with PBA episode counts at both day 30 and day 90 (Table 2) .
Safety
Among the 120 study participants who received DM/Q (the safety population), 43 CGI-C is a 7-point investigator-rated scale that assess overall treatment response with respect to PBA from baseline to day 90/final visit; PGI-C is a 7-point patient/patient's caregiver rated scale that assessed overall treatment response with respect to PBA from baseline to day 90/final visit. Percentages use the count of study participants with nonmissing data as the denominator (CGI-C, n=68; PGI-C, n=67) and may not sum to 100.0 due to rounding. CGI-C, Clinical Global Impression of Change; PGI-C, Patient/Caregiver Global Impression of Change. 
